COMMUNIQUÉS West-GlobeNewswire

Apricus Biosciences Announces Pricing of $3.55 Million Public Offering
28/03/2018
SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI ), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has priced a [...]
BioSig Announces Submission of FDA 510(k) Application for PURE EP System
28/03/2018
Santa Monica, CA, March 28, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) announced that the Company has filed 510(k) application to the U.S. Food and Drug Administration (FDA) for its first [...]
Aptose Biosciences Establishes New At-the-Market Facility
28/03/2018
SAN DIEGO and TORONTO, March 28, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO ) (TSX: APS ), a clinical-stage company developing highly differentiated therapeutics that [...]
Albireo to Present Clinical Data on A4250 at The International Liver Congress™ 2018
28/03/2018
BOSTON, March 28, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO ), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that new data from its [...]
Actinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actinium’s AWE Platform Technology
28/03/2018
- Collaborative research agreement will utilize Actinium’s AWE Technology Platform to generate Actinium Radio-Conjugates on selected Astellas targeting agents - Actinium to perform preclinical validation studies on [...]
FDA Grants Orphan Drug Designation to Cynata’s Lead Cymerus™ MSC Product, CYP-001
28/03/2018
MELBOURNE, Australia, March 28, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the United States Food and Drug [...]
BIOPHYTIS: 2017 Full Year Results
28/03/2018
Launch and progress in the SARA-OBS observational clinical study in the United States, Belgium, France, and Italy; Agencies’ authorizations of SARA-INT phase 2b interventional clinical study in the United States and [...]
3D Signatures Collaborates with MDxHealth to Evaluate Telo-PC™ Test in Prostate Cancer
28/03/2018
TORONTO, March 28, 2018 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V: DXD ) (OTCQB:TDSGF) (FSE:3D0) (the “Company” or " 3DS "), a personalized medicine company with a proprietary software platform (TeloView TM ) based [...]
Glycotope Selects CrownBio as a Preclinical Development Partner to Advance Their Immunotherapeutic Pipeline
28/03/2018
SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing [...]
Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol
28/03/2018
NEW YORK, March 28, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI ) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today announced receipt of [...]
Inovalon Announces New Post Acute Care Services Agreement with Tenet Healthcare
28/03/2018
BOWIE, Md., March 28, 2018 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV ), a leading technology company providing advanced, cloud-based platforms empowering a data-driven transformation from volume-based to value-based [...]
Precipio Files Patent for Non-Invasive Cell Capture Device For Gynecological Cancer Detection
28/03/2018
In collaboration with Yale, feminine panty liner designed to remove obstacles to early detection NEW HAVEN, Conn., March 28, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO ), [...]
MacroGenics Announces Pricing of Public Offering of Common Stock
28/03/2018
ROCKVILLE, MD, March 28, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for [...]
Mersana Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates
28/03/2018
Enrollment on Track for Phase 1 Trial of XMT-1522 Patients with Advanced Tumors Expressing HER2 Progressing Phase 1 Trial of XMT-1536, First-in-Class Dolaflexin ® Antibody Drug Conjugate Targeting NaPi2b Appointed David [...]
ICC Labs Signs Term Sheet to Acquire Equity Stake in Strategic Partner and Enter the European Market
28/03/2018
Highlights of proposed transaction, include ICC gaining: Access to five important European markets: Germany, United Kingdom, Spain, Italy and France. Use of an established multi-channel distribution network for CBD [...]
Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial of Its Lead Candidate DPX-Survivac Used in Combination with Pembrolizumab in Patients with DLBCL
28/03/2018
HALIFAX, Nova Scotia, March 28, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX: IMV ) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that the first patient has been treated in a Phase 2 Study [...]
Nexstim Plc: Decisions of the Board of Directors regarding Board Committees, approval of a financing arrangement and issuance of shares under the restricted share unit plan
28/03/2018
Company announcement, Helsinki, 28 March 2018, at 2 PM Nexstim Plc: Decisions of the Board of Directors regarding Board Committees, approval of a financing arrangement and issuance of shares under the restricted share [...]
Summit Therapeutics Selected for Emerging Science Presentation at the 2018 AAN Annual Meeting
28/03/2018
Summit Therapeutics plc ("Summit", or the "Company") Summit Therapeutics Selected for Emerging Science Presentation at the 2018 American Academy of Neurology Annual Meeting Oxford, UK, and Cambridge, MA, US, 28 March [...]
Edge Therapeutics Provides Update following Interim Analysis of Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
28/03/2018
Study Unlikely To Achieve Primary Efficacy Endpoint; DMC Recommends Discontinuation of Study No Unexpected Safety Findings Edge To Reduce Costs and Evaluate Next Steps Edge To Host Conference Call on Wednesday, March 28 [...]

Pages